跳至主要内容
临床试验/JPRN-jRCTs051210007
JPRN-jRCTs051210007进行中(未招募)2 期

Randomized controlled trial of the efficacy of supportive care during adjuvant chemotherapy in patients with gastric cancer - ACCORD

Motoori Masaaki0 个研究点目标入组 150 人开始时间: 2021年4月15日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 80age old(—)
性别
All

入选标准

  • 1. Patients with primary gastric cancer between the ages of 20 and 80 who underwent curative gastr
  • ectomy and scheduled to receive adjuvant chemotherapy with S1 or S1 plus docetaxel
  • 2. PS(ECOG) 0-1
  • 3. White blood cells > lower limit of normal (LLN) or 4000/mm3 and < 12000/mm3
  • 4.Neutrophils >1500/mm3
  • 5.Hemoglobin>8.0g/dL
  • 6.Aspartate aminotransferase (glutamic-oxaloacetic transaminase) (AST(GOT)) and alanine aminotransferase (glutamic-pyruvic transaminase) (ALT(GPT)) <3.0 x upper limit of normal (ULN) of the study site
  • 7.Total bilirubin <1.5mg/dL
  • 8.Creatinine <1.2mg/dL
  • 9.Creatinine clearance>60 mL/min

排除标准

  • 1. Patients with a history of intestinal resection other than gastrectomy, hepatectomy, or pancreatic resection
  • 2. Patients with simultaneous or metachronous cancer
  • 3. Patients with serious postoperative complications
  • 4. Patients with serious comorbidities, such as interstitial pneumonia, pulmonary fibrosis, uncontrolled diabetes, heart failure, renal failure, and liver cirrhosis
  • 5. Patients receiving systemic administration of steroids
  • 6. Patients taking flucytosine
  • 7. Patients taking warfarin potassium

研究者

发起方
Motoori Masaaki

相似试验